Skip to main content

Table 2 Incidence of biomarker variations and correlations with progression

From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Marker

All population

Progression

No progression

  

n = 103

%

n = 70

n = 33

p

Median delay (days)

ESR1

Mutated

22

21%

22 (31%)

0 (0%)

< 0.001

91 [0–282]

Non mutated

81

79%

48 (69%)

33 (100%)

  

> 25% CA-15.3 increase

Yes

47

46%

45 (64%)

2 (6%)

< 0.001

0 [0–543]

No

56

54%

25 (36%)

31 (94%)

  

> 100% CA-15.3 increase

Yes

25

24%

23 (33%)

2 (6%)

0.003

0 [0–91]

No

78

76%

47 (67%)

31 (94%)

  

> 25% DNA increase

Yes

91

88%

59 (84%)

32 (97%)

0.1

182 [0–635]

No

12

12%

11 (16%)

1 (3%)

  

> 100% DNA increase

Yes

55

53%

33 (42%)

22 (67%)

0.1

92 [0–474]

No

48

47%

37 (58%)

11 (33%)

  
  1. p values were determined using a chi-square test